Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2000
12/27/2000EP1061955A1 Polynucleotide composition, method of preparation, and use thereof
12/27/2000EP1061954A1 Poly(ethylene glycol) derivatives with proximal reactive groups
12/27/2000EP1061951A1 Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
12/27/2000EP1061947A1 Stabilized aqueous peptide solutions
12/27/2000EP1061946A1 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
12/27/2000EP1061931A2 Thrombin preparation and products and fibrin sealant methods employing same
12/27/2000EP1061915A1 Pharmaceutical formulations of taxanes
12/27/2000EP1061906A1 Monolithic tablet for controlled drug release
12/27/2000EP1061904A1 Nanoparticles, method for producing nanoparticles and use of the same
12/27/2000EP1061902A1 Colonic delivery of protein or peptide compositions
12/27/2000EP1061901A1 Nicotine inhaler
12/27/2000EP1061812A1 Food products having enhanced cocoa polyphenol content and processes for producing same
12/27/2000EP1061802A1 Topical carbamazepine formulations and methods of use
12/27/2000EP0627924B1 Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
12/27/2000EP0619730B1 Composition of antineoplastic agents incorporated in micelles
12/27/2000EP0613372B1 Subcutaneous implants based on nomegestrol derivatives
12/27/2000CN1278269A Piperazine-cyclodextrin complexes
12/27/2000CN1278175A Compositions of lipid lowering agents
12/27/2000CN1278174A Nicotine compositions and method for formulation thereof
12/27/2000CN1278173A Skin penetration enhancing components
12/27/2000CN1278171A Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent
12/27/2000CN1278165A Extended release formulation contg. venlafaxin
12/27/2000CN1278164A Solid state solutions and dispersions of poorly water soluble drugs
12/27/2000CN1278163A Microcrystalline cellulose/alginate pharmaceutical suspensions
12/27/2000CN1278162A Sustained release eyedrops
12/27/2000CN1277842A Chemical graft anti-gonococcus medicinal soluble cotton yarn, and it prepn. method
12/27/2000CN1277836A Novel cleaning agent component with improved characteristics of sedimentation and hair conditioning properties
12/27/2000CN1277835A Use of substituted vinyl tetrahydronaphthalene and vinyl benzotetrahydropyrane as light protecting agent
12/26/2000US6166199 Contacting purine with amino, hydrazine, hydroxylamine, thiol, semicarbazide, thiosemicarbazide, hydrazone, hydrazide, imidazole, tetrazole, triazole, pyrrolidine, piperidine, piperazine, morpholine, aldehyde, ketone, alcohol; antisense
12/26/2000US6166185 Antibodies to human TIE-2 ligands
12/26/2000US6166130 Providing synthetic polymer containing nucleophilic groups and second polymer containing electrophilic groups; contacting polymers to initiate crosslinking; simultaneously applying to tissue surface; crosslinking to form three-dimensional matrix
12/26/2000US6166062 Pharmaceutical compositions containing phospholipase inhibitor
12/26/2000US6166025 A stable, aqueous drug formulation for treating migraine
12/26/2000US6165996 Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis
12/26/2000US6165995 Cyclodextrin derivative in oil and water emulsion, said derivative substituted by at least one but no more than n-1 alkylacyl and alkenylacyl groups of linear hydrocarbon chains of at least eight carbon atoms and one sulfate group
12/26/2000US6165988 Copolymerizing an acrylic acid or methacrylic acid ester having a protected aminoalkyl group and a second acrylic acid or methacrylic acid or ester, removing the protecting group, binding the copolymer to an active substance by ionic bond
12/26/2000US6165987 A veterinary parasciticide dose containing a praziquantel, at least one macrolide anthelmintic selected from avermectins and milbemycins and a solvent selected from glycerol formal, ethyl lactate, benzyl alcohol and n-metyl-2-pyrrollidone
12/26/2000US6165984 Administering an effective amount of naringin or naringenin to the human to prevent acylcoa-cholesterol-o-acyltransferase activity to treat hepatic diseases; inhibiting accumulation of macrophage-lipid complex on the arterial endothelium
12/26/2000US6165979 Glutathion disulfide which is an oxidized glutathion when administered parenteral induces the endogenous cytokine and/or hematopoietic factor; used for neoplastic, infectious, hematologic, immunologic or other diseases
12/26/2000US6165974 Administering an effective dose of a pharmaceutical preparation comprising at least two coagulation factors which are components of a prothrombinase or of a pro-prothrombinase to the patient for the treatment of acute bleeding
12/26/2000US6165787 Regulated transcription of targeted genes and other biological events
12/26/2000US6165779 Recombinant virus vector such as tumor suppressor gene formulated in a buffer comprising a detergent; for gene therapy of cancer; buffer comprising a delivery-enhancing agent
12/26/2000US6165772 Simple and cost-effective preparation of vehicle for delivery of dna, rna, protein, peptide nucleic acids, or lipophilic drugs
12/26/2000US6165745 Recombinant production of immunoglobulin-like domains in prokaryotic cells
12/26/2000US6165513 Film-coated tablet for improved upper gastrointestinal tract safety
12/26/2000US6165511 Polyol composition
12/26/2000US6165508 Controlled release of metal cation-stabilized interferon
12/26/2000US6165507 Slow-release pharmaceutical formulations containing mizolastine
12/26/2000US6165506 A solid dose nanoparticulate naproxen formulation having a high rate of dissolution comprising a naproxen having specific particle size, polyvinylpyrrolidone adsorbed on the surface and an alkali agent to increase the dissolution rate
12/26/2000US6165503 Preparing gelled beads of a polyanionic polysaccharide which are cross-linked with a polyvalent cation, forming capsules having polycationic-polyanion membrane of polycationic polysaccharide on gelled beads, culturing the product capsule
12/26/2000US6165493 "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
12/26/2000US6165492 Intrauterine chemical necrosing method, composition, and apparatus
12/26/2000US6165484 EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
12/26/2000US6165481 Highly pure squalane, raw material for pharmaceuticals and cosmetics prepared by using the same and method for producing the same
12/26/2000US6165466 Antagonists of interleukin-15
12/26/2000US6165464 Monoclonal antibodies directed to the HER2 receptor
12/26/2000US6165458 Composition and method for dermal and transdermal administration of a cytokine
12/26/2000US6165445 Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
12/26/2000US6165440 Radiation and nanoparticles for enhancement of drug delivery in solid tumors
12/26/2000CA2312512A1 Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets
12/26/2000CA2044878C Thermally reversible and irreversible gels
12/21/2000WO2000077227A1 Fibrin sealant as a transfection/transformation vehicle for gene therapy
12/21/2000WO2000077032A2 Spermine:peptide-based surfactant compounds
12/21/2000WO2000076954A1 Polyhydroxy diamine surfactants and their use in gene transfer
12/21/2000WO2000076555A1 Gel composition for filing a breast milk duct prior to surgical excision of the duct or other breast tissue
12/21/2000WO2000076554A1 Ligand-conjugated oligomeric compounds
12/21/2000WO2000076553A1 Use of viral vectors and charged molecules for gene therapy
12/21/2000WO2000076551A2 Method for producing an injectable medicament preparation
12/21/2000WO2000076550A2 Carrier-drug conjugate
12/21/2000WO2000076548A1 Filler binder for tablets
12/21/2000WO2000076543A1 Ocular tension lowering composition for topical adminstration
12/21/2000WO2000076535A1 Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
12/21/2000WO2000076533A1 Hemoactive compositions and methods for their manufacture and use
12/21/2000WO2000076528A2 Pharmaceutical preparation containing proteins
12/21/2000WO2000076525A1 Anticancer emulsions containing anthracycline compounds
12/21/2000WO2000076520A1 Antifungal oral composition containing itraconazole and process for preparing same
12/21/2000WO2000076509A1 Nasal delivery of apomorphine
12/21/2000WO2000076507A1 Method for increasing the solubility of morphine and pharmaceutical compositions prepared therefrom
12/21/2000WO2000076506A1 Pharmaceutical formulations and methods comprising intranasal morphine
12/21/2000WO2000076496A1 Tumor tissue accumulation enhancers for drugs
12/21/2000WO2000076489A2 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
12/21/2000WO2000076482A1 Novel formulations comprising lipid-regulating agents
12/21/2000WO2000076481A1 Mesalazine controlled release oral pharmaceutical compositions
12/21/2000WO2000076478A1 Controlled release and taste masking oral pharmaceutical compositions
12/21/2000WO2000076475A1 Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
12/21/2000WO2000076464A2 Oxidatively stable, long-chain ethyl ester emollients
12/21/2000WO2000076453A2 Emzyme-assisted cell death
12/21/2000WO2000076315A1 Transdermally delivered aspirin
12/21/2000WO2000076314A1 Compositions and methods comprising morphine gluconate
12/21/2000WO2000052049A3 A method for purifying human growth hormone
12/21/2000WO2000050088A3 Biotinylated-chemokine antibody complexes
12/21/2000WO2000050008A3 Antibody fragment-targeted immunoliposomes for systemic gene delivery
12/21/2000WO2000048621A3 Methods and compositions for regulating protein-protein interactions
12/21/2000WO2000045791A3 Method for controlling liposome size
12/21/2000WO2000044367A3 A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
12/21/2000WO2000028972A3 Nanocapsules and method of production thereof
12/21/2000WO1999059572A8 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
12/21/2000WO1998006436A3 Inhibiting undesirable taste in oral compositions
12/21/2000DE19928112A1 Balanced mixtures of Guerbet alcohols, including new 2-hexyl-1-tetradecanol, useful as oil components of cosmetic and pharmaceutical compositions
12/21/2000DE19928033A1 Verwendung von cyclischen Enaminen als Lichtschutzmittel The use of cyclic enamines as light stabilizers
1 ... 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 ... 1712